we are also commercializing the unyvero lrt bal test for testing bronchoalveolar lavage , or bal , specimens from patients with lower respiratory tract infections following fda clearance received by curetis in december 2019. the unyvero lrt bal automated test simultaneously detects 20 pathogens and 10 antibiotic resistance markers , and it is the first and only fda-cleared panel that now also includes pneumocystis jirovecii , a key fungal pathogen often found in immunocompromised patients that can be difficult to diagnose as the 20 th pathogen on the panel . we believe the unyvero lrt and lrt bal tests have the ability to help address a significant , previously unmet medical need that causes over $ 10 billion in annual costs for the u.s. healthcare system , according to the centers for disease control , or cdc . · the unyvero urinary tract infection , or uti , test which is ce-ivd marked in europe is currently being made available to laboratories in the u.s. as a research use only or ruo kit . the test detects a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimens . as part of our portfolio strategy update on october 13 , 2020 , we have decided to proceed with the analytical and clinical performance evaluation including clinical trials required for a subsequent u.s. fda submission . · the unyvero invasive joint infection , or iji , test , which is a variant developed for the u.s. market based on the ce-ivd-marked european unyvero iti test , has also been selected for analytical and clinical performance evaluation including clinical trials towards a future u.s. fda submission . microbial diagnosis of iji is difficult because of challenges in sample collection , usually at surgery , and patients being on prior antibiotic therapy which minimizes the chances of recovering viable bacteria . we believe that unyvero iji could be useful in identifying pathogens as well as their amr markers to help guide optimal antibiotic treatment for these patients . 55 · the acuitas amr gene panel ( isolates ) is currently pending final fda review and a potential clearance decision . the fda recently notified us that the agency plans to continue prioritizing emergency use authorization requests for diagnostic products intended to address the covid-19 pandemic for at least the remainder of the year , which will impact the statutory review periods for submissions , including the potential clearance decision on our acuitas amr gene panel ( isolates ) submission . despite the fda having informed us of their resumed review at the end of january 2021 of the responses filed by opgen to the ai letters , the fda still does not commit to any mdufa timelines . once fda cleared , we expect to commercialize the acuitas amr gene panel for isolates more broadly to customers in the u.s. the acuitas amr gene panel ( urine ) test has been discontinued as part of the october 13 , 2020 portfolio and pipeline strategy review . · we are also developing novel bioinformatics tools and solutions to accompany or augment our current and potential future ivd products and may seek regulatory clearance for such bioinformatics tools and solutions to the extent they would be required either as part of our portfolio of ivd products or even as a standalone bioinformatics product . opgen has extensive offerings of additional in vitro diagnostic tests including ce-ivd-marked unyvero tests for hospitalized pneumonia patients , implant and tissue infections , intra-abdominal infections , complicated urinary tract infections , and blood stream infections . our portfolio furthermore includes a ce-ivd-marked pcr based rapid test kit for sars cov-2 detection in combination with our pcr compatible universal lysis buffer ( pulb ) which we also market as a stand-alone ruo reagent . opgen 's combined amr bioinformatics offerings , once such products are cleared for marketing , if ever , will offer important new tools to clinicians treating patients with amr infections . we have collaborated with merck , inc. to establish the acuitas lighthouse knowledgebase , which is currently commercially available in the united states for ruo . the acuitas lighthouse knowledgebase includes approximately 15,000 bacterial isolates from the merck smart surveillance network of 192 hospitals in 52 countries and other sources . ares genetics ' aresdb is a comprehensive database of genetic and phenotypic information . aresdb was originally designed based on the siemens microbiology strain collection covering resistant pathogens and its development has significantly expanded , also by transferring data from the acuitas lighthouse® into aresdb to now cover approximately 55,000 bacterial isolates that have been sequenced using ngs technology and tested for susceptibility with applicable antibiotics from a range of over 100 antimicrobial drugs . in september 2019 , ares genetics signed a technology evaluation agreement with an undisclosed global ivd corporation . in the collaboration , ares genetics further enriched aresdb with a focus on certain pathogens relevant in a first , undisclosed infectious disease indication . following the successful completion of this collaborative r & d project , the ivd partner exercised their option for a 90-day period of exclusive negotiations with ares genetics for a potential exclusive license to aresdb in the field of human clinical diagnostics . following the lapse of such 90-day period without any commercial deal being signed , ares genetics is now in multiple , nonexclusive parallel discussions with several interested parties and such discussions are ongoing . in addition to potential future licensing and partnering , opgen 's subsidiary ares genetics intends to independently utilize the proprietary biomarker content in these databases , as well as to build an independent business in ngs and ai based offerings for amr research and diagnostics in collaboration with its current and potential future partners in the life science , pharmaceutical and diagnostics industries . story_separator_special_tag critical estimates in valuing certain intangible assets include but are not limited to future expected cash flows from customer/distributions relationships , developed technology , and in-process research & development discount rates , and terminal values . our estimate of fair value is based upon assumptions believed to be reasonable , but actual results may differ from estimates . we determine the fair value of assumed debt using a discounted cash flow analysis using interest rates for debt with similar terms and maturities . differences between the fair value and the stated value is recorded as a discount or premium and amortized over the remaining term using the effective interest method . we utilize a monte carlo simulation method to determine the fair value of conversion notes , which utilizes inputs including the common stock price , volatility of common stock , the risk-free interest rate and the probability of conversion to common shares at the conversion rate . other estimates associated with the accounting for the acquisition may change as additional information becomes available regarding the assets acquired and liabilities assumed , as more fully discussed in note 4 – business combination of the notes to the consolidated financial statements ( part ii , item 8 of this form 10-k ) . 61 revenue recognition the company derives revenues from ( i ) the sale of quickfish and pna fish diagnostic test products , unyvero application cartridges , unyvero systems , sars cov-2 tests , acuitas amr gene panel ruo test products , ( ii ) providing laboratory services , and ( iii ) providing collaboration services including funded software arrangements , and license arrangements . the company analyzes contracts to determine the appropriate revenue recognition using the following steps : ( i ) identification of contracts with customers , ( ii ) identification of distinct performance obligations in the contract , ( iii ) determination of contract transaction price , ( iv ) allocation of contract transaction price to the performance obligations and ( v ) determination of revenue recognition based on timing of satisfaction of the performance obligation . the company recognizes revenues upon the satisfaction of its performance obligation ( upon transfer of control of promised goods or services to our customers ) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services . the company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer . the company had no material incremental costs to obtain customer contracts in any period presented . deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided . impairment of long-lived assets property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable . recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset . recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets . if such assets are considered to be impaired , impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets . definite-lived intangible assets include trademarks , developed technology , software and customer relationships . if any indicators were present , the company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset . if those net undiscounted cash flows do not exceed the carrying amount ( i.e . , the asset is not recoverable ) , the company would perform the next step , which is to determine the fair value of the asset and record an impairment loss , if any . acquired in-process research & development represents the fair value assigned to those research and development projects that were acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use . ipr & d is capitalized at its fair value as an indefinite-lived intangible asset , and any development costs incurred after the acquisition are expensed as incurred . upon achieving regulatory approval or commercial viability for the related product , the indefinite-lived intangible asset is accounted for as a finite-lived asset and is amortized on a straight-line basis over the estimated useful life . if the project is not completed or is terminated or abandoned , the company may have an impairment related to the ipr & d which is charged to expense . indefinite-lived intangible assets are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may be impaired . impairment is calculated as the excess of the asset 's carrying value over its fair value . goodwill represents the excess of the purchase price paid when the company acquired advandx , inc. in july 2015 and curetis in april 2020 , over the fair values of the acquired tangible or intangible assets and assumed liabilities . the company will conduct an impairment test of goodwill on an annual basis as of december 31 of each year and will also conduct tests if events occur or circumstances change that would , more likely than not , reduce the company 's fair value below its net equity value . share-based compensation share-based payments to employees , directors and consultants are recognized at fair value . the resulting fair value is recognized ratably over the requisite service period , which is generally the vesting period of the option . the estimated fair value of equity instruments issued to nonemployees is recorded at fair value on

liquidity and capital resources at december 31 , 2020 , the company had cash and cash equivalents of $ 13.4 million , compared to $ 2.7 million at december 31 , 2019. the company has funded its operations primarily through external investor financing arrangements and has raised significant funds in 2020 and 2019 , including : on november 25 , 2020 , the company closed the 2020 pipe of 2,245,400 shares of common stock together with 2,597,215 pre-funded warrants . the 2020 pipe raised aggregate net proceeds of $ 9.3 million , and gross proceeds of $ 10.0 million . on february 11 , 2020 , we entered into the 2020 atm agreement , pursuant to which we may offer and sell from time to time at our option , up to an aggregate of $ 22.1 million of shares of our common stock through the sales agents . during the year ended december 31 , 2020 , the company sold 7,521,610 shares of its common stock under the 2020 atm offering resulting in aggregate net proceeds of approximately $ 15.8 million , and gross proceeds of $ 16.7 million . 59 during the year ended december 31 , 2020 , approximately 4.3 million common warrants issued in the company 's october 2019 public offering were exercised raising net proceeds of approximately $ 8.7 million . on october 28 , 2019 , the company closed the october 2019 public offering of 2,590,170 units at $ 2.00 per unit and 2,109,830 pre-funded units at $ 1.99 per pre-funded unit .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources at december 31 , 2020 , the company had cash and cash equivalents of $ 13.4 million , compared to $ 2.7 million at december 31 , 2019. the company has funded its operations primarily through external investor financing arrangements and has raised significant funds in 2020 and 2019 , including : on november 25 , 2020 , the company closed the 2020 pipe of 2,245,400 shares of common stock together with 2,597,215 pre-funded warrants . the 2020 pipe raised aggregate net proceeds of $ 9.3 million , and gross proceeds of $ 10.0 million . on february 11 , 2020 , we entered into the 2020 atm agreement , pursuant to which we may offer and sell from time to time at our option , up to an aggregate of $ 22.1 million of shares of our common stock through the sales agents . during the year ended december 31 , 2020 , the company sold 7,521,610 shares of its common stock under the 2020 atm offering resulting in aggregate net proceeds of approximately $ 15.8 million , and gross proceeds of $ 16.7 million . 59 during the year ended december 31 , 2020 , approximately 4.3 million common warrants issued in the company 's october 2019 public offering were exercised raising net proceeds of approximately $ 8.7 million . on october 28 , 2019 , the company closed the october 2019 public offering of 2,590,170 units at $ 2.00 per unit and 2,109,830 pre-funded units at $ 1.99 per pre-funded unit .
```    
 Suspicious Activity Report : we are also commercializing the unyvero lrt bal test for testing bronchoalveolar lavage , or bal , specimens from patients with lower respiratory tract infections following fda clearance received by curetis in december 2019. the unyvero lrt bal automated test simultaneously detects 20 pathogens and 10 antibiotic resistance markers , and it is the first and only fda-cleared panel that now also includes pneumocystis jirovecii , a key fungal pathogen often found in immunocompromised patients that can be difficult to diagnose as the 20 th pathogen on the panel . we believe the unyvero lrt and lrt bal tests have the ability to help address a significant , previously unmet medical need that causes over $ 10 billion in annual costs for the u.s. healthcare system , according to the centers for disease control , or cdc . · the unyvero urinary tract infection , or uti , test which is ce-ivd marked in europe is currently being made available to laboratories in the u.s. as a research use only or ruo kit . the test detects a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimens . as part of our portfolio strategy update on october 13 , 2020 , we have decided to proceed with the analytical and clinical performance evaluation including clinical trials required for a subsequent u.s. fda submission . · the unyvero invasive joint infection , or iji , test , which is a variant developed for the u.s. market based on the ce-ivd-marked european unyvero iti test , has also been selected for analytical and clinical performance evaluation including clinical trials towards a future u.s. fda submission . microbial diagnosis of iji is difficult because of challenges in sample collection , usually at surgery , and patients being on prior antibiotic therapy which minimizes the chances of recovering viable bacteria . we believe that unyvero iji could be useful in identifying pathogens as well as their amr markers to help guide optimal antibiotic treatment for these patients . 55 · the acuitas amr gene panel ( isolates ) is currently pending final fda review and a potential clearance decision . the fda recently notified us that the agency plans to continue prioritizing emergency use authorization requests for diagnostic products intended to address the covid-19 pandemic for at least the remainder of the year , which will impact the statutory review periods for submissions , including the potential clearance decision on our acuitas amr gene panel ( isolates ) submission . despite the fda having informed us of their resumed review at the end of january 2021 of the responses filed by opgen to the ai letters , the fda still does not commit to any mdufa timelines . once fda cleared , we expect to commercialize the acuitas amr gene panel for isolates more broadly to customers in the u.s. the acuitas amr gene panel ( urine ) test has been discontinued as part of the october 13 , 2020 portfolio and pipeline strategy review . · we are also developing novel bioinformatics tools and solutions to accompany or augment our current and potential future ivd products and may seek regulatory clearance for such bioinformatics tools and solutions to the extent they would be required either as part of our portfolio of ivd products or even as a standalone bioinformatics product . opgen has extensive offerings of additional in vitro diagnostic tests including ce-ivd-marked unyvero tests for hospitalized pneumonia patients , implant and tissue infections , intra-abdominal infections , complicated urinary tract infections , and blood stream infections . our portfolio furthermore includes a ce-ivd-marked pcr based rapid test kit for sars cov-2 detection in combination with our pcr compatible universal lysis buffer ( pulb ) which we also market as a stand-alone ruo reagent . opgen 's combined amr bioinformatics offerings , once such products are cleared for marketing , if ever , will offer important new tools to clinicians treating patients with amr infections . we have collaborated with merck , inc. to establish the acuitas lighthouse knowledgebase , which is currently commercially available in the united states for ruo . the acuitas lighthouse knowledgebase includes approximately 15,000 bacterial isolates from the merck smart surveillance network of 192 hospitals in 52 countries and other sources . ares genetics ' aresdb is a comprehensive database of genetic and phenotypic information . aresdb was originally designed based on the siemens microbiology strain collection covering resistant pathogens and its development has significantly expanded , also by transferring data from the acuitas lighthouse® into aresdb to now cover approximately 55,000 bacterial isolates that have been sequenced using ngs technology and tested for susceptibility with applicable antibiotics from a range of over 100 antimicrobial drugs . in september 2019 , ares genetics signed a technology evaluation agreement with an undisclosed global ivd corporation . in the collaboration , ares genetics further enriched aresdb with a focus on certain pathogens relevant in a first , undisclosed infectious disease indication . following the successful completion of this collaborative r & d project , the ivd partner exercised their option for a 90-day period of exclusive negotiations with ares genetics for a potential exclusive license to aresdb in the field of human clinical diagnostics . following the lapse of such 90-day period without any commercial deal being signed , ares genetics is now in multiple , nonexclusive parallel discussions with several interested parties and such discussions are ongoing . in addition to potential future licensing and partnering , opgen 's subsidiary ares genetics intends to independently utilize the proprietary biomarker content in these databases , as well as to build an independent business in ngs and ai based offerings for amr research and diagnostics in collaboration with its current and potential future partners in the life science , pharmaceutical and diagnostics industries . story_separator_special_tag critical estimates in valuing certain intangible assets include but are not limited to future expected cash flows from customer/distributions relationships , developed technology , and in-process research & development discount rates , and terminal values . our estimate of fair value is based upon assumptions believed to be reasonable , but actual results may differ from estimates . we determine the fair value of assumed debt using a discounted cash flow analysis using interest rates for debt with similar terms and maturities . differences between the fair value and the stated value is recorded as a discount or premium and amortized over the remaining term using the effective interest method . we utilize a monte carlo simulation method to determine the fair value of conversion notes , which utilizes inputs including the common stock price , volatility of common stock , the risk-free interest rate and the probability of conversion to common shares at the conversion rate . other estimates associated with the accounting for the acquisition may change as additional information becomes available regarding the assets acquired and liabilities assumed , as more fully discussed in note 4 – business combination of the notes to the consolidated financial statements ( part ii , item 8 of this form 10-k ) . 61 revenue recognition the company derives revenues from ( i ) the sale of quickfish and pna fish diagnostic test products , unyvero application cartridges , unyvero systems , sars cov-2 tests , acuitas amr gene panel ruo test products , ( ii ) providing laboratory services , and ( iii ) providing collaboration services including funded software arrangements , and license arrangements . the company analyzes contracts to determine the appropriate revenue recognition using the following steps : ( i ) identification of contracts with customers , ( ii ) identification of distinct performance obligations in the contract , ( iii ) determination of contract transaction price , ( iv ) allocation of contract transaction price to the performance obligations and ( v ) determination of revenue recognition based on timing of satisfaction of the performance obligation . the company recognizes revenues upon the satisfaction of its performance obligation ( upon transfer of control of promised goods or services to our customers ) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services . the company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer . the company had no material incremental costs to obtain customer contracts in any period presented . deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided . impairment of long-lived assets property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable . recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset . recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets . if such assets are considered to be impaired , impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets . definite-lived intangible assets include trademarks , developed technology , software and customer relationships . if any indicators were present , the company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset . if those net undiscounted cash flows do not exceed the carrying amount ( i.e . , the asset is not recoverable ) , the company would perform the next step , which is to determine the fair value of the asset and record an impairment loss , if any . acquired in-process research & development represents the fair value assigned to those research and development projects that were acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use . ipr & d is capitalized at its fair value as an indefinite-lived intangible asset , and any development costs incurred after the acquisition are expensed as incurred . upon achieving regulatory approval or commercial viability for the related product , the indefinite-lived intangible asset is accounted for as a finite-lived asset and is amortized on a straight-line basis over the estimated useful life . if the project is not completed or is terminated or abandoned , the company may have an impairment related to the ipr & d which is charged to expense . indefinite-lived intangible assets are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may be impaired . impairment is calculated as the excess of the asset 's carrying value over its fair value . goodwill represents the excess of the purchase price paid when the company acquired advandx , inc. in july 2015 and curetis in april 2020 , over the fair values of the acquired tangible or intangible assets and assumed liabilities . the company will conduct an impairment test of goodwill on an annual basis as of december 31 of each year and will also conduct tests if events occur or circumstances change that would , more likely than not , reduce the company 's fair value below its net equity value . share-based compensation share-based payments to employees , directors and consultants are recognized at fair value . the resulting fair value is recognized ratably over the requisite service period , which is generally the vesting period of the option . the estimated fair value of equity instruments issued to nonemployees is recorded at fair value on

